[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"upper-tract-urothelial-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:upper-tract-urothelial-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,73,104,126,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644810","specimen-collection-for-validation-of-uroamp-a-next-generation-sequencing-platform-for-detection-and-surveillance-of-bladder-cancer-100644810",false,"NCT07673016","Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer","INSITE","Inclusion Criteria:\n\nGROUP 1: Bladder Cancer and\u002For Upper Tract UCC\n\n* Male or female ≥ 18 years of age who are scheduled for transurethral resection of bladder tumor (TURBT) and\u002For biopsy of urinary tract or\n* Patients on surveillance who are negative for recurrence or tumor at the time of study enrollment but have had previous urothelial cell carcinoma (UCC) or\n* Patients with muscle invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC) scheduled for NAC and\u002For subsequent radical cystectomy (RC)\n* Able to provide consent prior to diagnostic TURBT, nephroureterectomy, or administration of NAC and\u002For RC\n* Able to provide at least 20cc urine. If patient cannot void sufficient volume of urine, urologist can pull urine from the bladder via catheter or cystoscope. Urine should not be collected immediately after resection\n* Participation in other bladder cancer studies is allowed. Experimental therapy must be documented in the case report forms\n\nGROUP 2: Hematuria Controls\n\n* Male or female ≥ 18 years of age presenting with gross or microscopic hematuria as defined by standard of care\n* No evidence of and\u002For history of bladder cancer, upper tract UCC, kidney cancer and\u002For prostate cancer at the time of collection\n* Able to provide consent\n* Able to provide at least 20cc urine\n* Participation in other studies is allowed. Experimental therapy must be documented in the case report forms\n\nExclusion Criteria:\n\nGROUP 1: Bladder Cancer and\u002For Upper Tract UCC\n\n* Clinical, symptomatic urinary tract infection at time of initial urine collection\n* Unable to provide adequate urine sample\n\nGROUP 2: Hematuria Controls\n\n\\- Evidence and\u002For History of bladder cancer, upper tract UCC, kidney cancer and\u002For prostate cancer at the time of collection","ALL","18 Years",{"count":19,"type":20},2500,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.",[24,25,26,27],"Bladder Cancer","Urothelial Carcinoma (UC)","Hematuria","Upper Tract Urothelial Cancer",[29,30,31,32],"Non-muscle invasive bladder cancer","Muscle invasive bladder cancer","Upper tract urothelial carcinoma","Urine tumor DNA","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2019-10-15",{"date":41,"type":20},"2034-12",{"name":43,"class":44},"Convergent Genomics, Inc.","NETWORK",23,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100578002","urine-methylation-markers-in-utuc-100578002","NCT06805630","Urine Methylation Markers in UTUC","Urine-based Methylation Markers in the Diagnosis and Surveillance of Upper Tract Urothelial Carcinoma","Inclusion Criteria:\n\n* \\>=18 years\n* Primary UTUC\n\nExclusion Criteria:\n\n* Patients who do not understand and\u002For are unwilling to sign a written informed consent",{"count":54,"type":20},50,"INTERVENTIONAL",[57],"NA","This is a research study to measure DNA markers in the urine of patients with upper tract urothelial cancer (UTUC) before surgery and during follow-up visits. Identifying these DNA markers could improve diagnosis before surgery, help assess risk, and predict early recurrence of the cancer. Urine samples will be de-identified and sent to Pangea Laboratory LLC for analysis. The results of this test will be compared to the traditional tests in upper tract urothelial cancer, such as cells in the urine and tissue biopsy.",[27],[61],"UTUC","2026-05-28",{"date":64,"type":37},"2026-06-01",{"date":66,"type":37},"2025-05-07",{"date":68,"type":20},"2026-06-30",{"name":70,"class":71},"Duke University","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":72},"100579262","phase-2-sequential-gemcitabine-and-mitomycin-treatment-for-favorable-high-risk-upper-urinary-tract-urothelial-carcinoma-100579262","NCT06822010","SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma","A Phase II Trial of SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT)","Inclusion Criteria:\n\n* Subjects must meet all of the following applicable inclusion criteria to participate in the study:\n\n  1. Patient has signed Informed Consent Form and is willing and able to comply with all requirements of the protocol.\n  2. Patient is at least 18 years of age.\n  3. Naive or recurrent patients with High Grade Ta +\u002F- CIS, non-invasive UTUC in the upper tract (pyelocalyceal system or ureter).\n* Histologic confirmation with biopsy is necessary.\n* All patients must undergo ureteroscopy with biopsy.\n* Non-Invasive Papillary Carcinoma (HGTa) lesions must be maximally ablated with ≤ 15 mm residual papillary disease in total.\n\n  4\\. Favorable high-grade upper tract urothelial carcinoma (UTUC) as per American Urological Association (AUA) risk stratification below (except that multifocality, obstruction, ureteral involvement, bladder involvement will be allowed).\n  1. If the bladder is involved with NMIBC it should be treated prior to or during Gem\u002FJel treatments.\n\n     5\\. Patients with ECOG (Eastern Cooperative Oncology Group) performance status \\\u003C3 (with Karnofsky \\>40).\n\n     6\\. Patients with life expectancy greater than 24 months at time of screening. 7. Patient has no active urinary tract infection (UTI) as confirmed by urine culture or urinalysis\\*.\n\n     8\\. Female Patients of childbearing potential\\*\\*, must have a negative serum pregnancy test at screening and must agree to use two acceptable \\& effective methods of contraception\\*\\*\\*, until 6 months post treatment 9. All sexually active male patients must agree to use a condom during intercourse, for at least 48 hours post each instillation.\n\n     10\\. Male patients who have a partner that is a female of childbearing potential must agree to use two acceptable \\& effective methods of contraception until 6 months post treatment.\n\n     11\\. Patients must not have any other medical condition(s) that make(s) their participation in the study unadvisable in the opinion of the investigator.\n\n     Exclusion Criteria:\n\n     Invasive upper tract urothelial carcinoma (suspected cT2-4 on imaging) or lymphadenopathy (cN1-3) Bilateral disease Patient is actively being treated or intends to be treated with systemic chemotherapy during the duration of the trial.\n\n     4\\. Any other malignancy diagnosed within 2 years of trial entry with the exception of:\n\n  a. Basal or squamous cell skin cancers, or b. Noninvasive cancer of the cervix, or c. Any other cancer deemed to be of low-risk for progression or patient morbidity during trial period (basal or squamous cell skin cancers, noninvasive cancer of the cervix, prostate cancer under active surveillance, renal cancer under active surveillance).\n\n  4\\. Administration not feasible via nephrostomy tube. 5. Inability to deliver the investigational drug to the pyelocalyceal system. 6. Patient has any other medical or mental condition(s) that make(s) his\u002Fher participation in the trial unadvisable in the opinion of the treating urologist.\n\n  7\\. Patient has contraindication to mitomycin C (MMC )treatment, or known sensitivity to MMC.\n\n  8\\. Patient has an intractable bleeding disorder (e.g., coagulation factors deficiencies, Von Willebrand Disease).\n\n  9\\. Patient is currently receiving any other investigational agents or has participated in a research protocol involving administration of an investigational product within the past 30 days prior to Visit 1.\n\n  10\\. Pregnant (positive serum pregnancy test), planning to become pregnant during the trial period, breast-feeding, or of childbearing potential and not practicing reliable contraception\\*\\*\\*.\n\n  \\* In case of a symptomatic UTI the patient will be treated with a full course of antibiotics, and the instillation will be postponed until resolution. In the case of asymptomatic bacteriuria, the use of prophylactic antibiotics and postponement of the treatment is left to the discretion of the PI.\n\n  \\*\\* Women of non-childbearing potential:\n  1. At least 12 months since the last menses, or\n  2. Without uterus and\u002For both ovaries, or\n  3. Has been surgically sterile for at least 6 months prior to trial drug administration.\n\n     * Acceptable methods of birth control which are considered to have a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectable, combined (estrogen\u002Fprogesterone) oral contraceptives, intrauterine devices (IUDs-only hormonal), condoms with spermicide, sexual abstinence or vasectomized partner.","99 Years",{"count":82,"type":20},28,[84],"PHASE2","This Phase II clinical trial, titled \"A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT),\" aims to evaluate the safety and effectiveness of a combination chemotherapy treatment for patients with favorable papillary high-grade upper tract urothelial carcinoma (UTUC). The study focuses on sequential administration of two drugs, gemcitabine and Jelmyto (a gel-based form of mitomycin), to potentially preserve kidney function and avoid nephroureterectomy (kidney removal), which is the current standard of care for participants with non-endoscopically resectable tumors.",[87,27,88],"Urinary Bladder Cancer","Urothelial Cancer",[90,91,92,93,94],"upper tract urothelial cancer","urothelial cancer","gemcitabine","jelmyto","mitomycin","2026-05-02",{"date":97,"type":37},"2026-05-06",{"date":99,"type":37},"2026-03-06",{"date":101,"type":20},"2029-04-01",{"name":103,"class":71},"Rutgers, The State University of New Jersey",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":55,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":72},"100591986","single-port-ras-using-da-vinci-sp-surgical-system-for-utuc-patients-100591986","NCT06987552","Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients","A Pilot Study of Single-Port Robot-Assisted Surgery Using Da Vinci SP Surgical System for Patients With Upper Tract Urothelial Cancer","Inclusion Criteria:\n\n* Age 20 years or more\n* Histologically or cytologically diagnosed upper tract urothelial cancer\n* Fitting indications of radical nephroureterectomy and ipsilateral bladder cuff resection, and deemed feasible for robotic surgery\n* ASA physical status classification 1-2 and adequate organ function\n* Patients willing and able to comply with study protocol requirements and follow-up\n* With informed consent\n\nExclusion Criteria:\n\n* Synchronous bladder cancer\n* Distant metastasis of cancer\n* BMI ≥30 or BMI \\\u003C18.5\n* Unable to tolerate lateral decubitus or Trendelenburg position (relative contra-indication)\n* Severe adhesion due to prior abdominopelvic surgery (relative contra-indication)\n* Previous radiation treatment to the pelvic area\n* Active infectious disease\n* Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions, such as: severe heart disease (NYHA functional class III-IV) or severe lung disease (GOLD Group C-D)\n* Cannot follow trial-required procedures\n* Concomitant systemic or pelvic disease that increases the risk of surgery\n* Long-term use of anti-coagulant(s)\n* Patients with coagulopathy\n* Emergency surgery","20 Years",{"count":113,"type":20},25,[57],"To evaluate patient-reported outcomes of radical nephroureterectomy using single-port robotic surgery",[27],"2025-05-15",{"date":119,"type":37},"2025-05-23",{"date":121,"type":37},"2024-12-24",{"date":123,"type":20},"2026-01-01",{"name":125,"class":71},"National Taiwan University Hospital",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":55,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":72},"100579127","phase-4-ddr-genes-alteration-and-response-to-platinum-based-chemotherapy-in-advanced-urothelial-cancer-100579127","NCT06820255","DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.","Prospective Evaluation of the DDR Genes Alteration to Predict Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.","SELECTIO-UC","Inclusion Criteria:\n\n1. Informed consent obtained before any study-specific procedures. Patients must be able to understand and be willing to sign a written informed consent.\n2. Male or female patient ≥18 years of age.\n3. Histological or cytological documentation of urothelial cancer.\n4. Available tumor tissue for analysis\n5. Measurable disease according to Response Evaluation Criteria in Solid Tumors criteria, version 1.1.\n6. Eastern Cooperative Oncology Group performance status of ≤2. (Patients with ECOG PS of 2 were required to also meet the additional criteria: hemoglobin ≥10 g\u002FdL, GFR ≥50mL\u002Fmin, may not have NYHA class III heart failure).\n7. Life expectancy of at least 6 months.\n8. Eligible to standard chemotherapy with cisplatin or carboplatin + gemcitabine as per clinical practice.\n9. Women of childbearing potential and men must agree to use adequate contraception since signing of the informed consent form until 180 days after the last dose of chemotherapy and 30 days after the last dose of avelumab. The investigator or a designated associate is requested to advise the subject how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically recommend method (or combination of methods) as per standard of care.\n10. Adequate bone-marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment:\n\na Creatinine value \\\u003C2.5 mg\u002Fdl and creatinine clearance \\> 30 ml\u002Fmin evaluated by the Cockcroft-Gault Formula.\n\nb Total bilirubin ≤1∙5 × the upper limit of normal (ULN); c Alanine aminotransferase and aspartate aminotransferase ≤2 × ULN (≤5 × ULN for patients with liver involvement of their cancer); d International normalized ratio (INR) and partial thromboplastin time (PTT) ≤1∙5 × ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no prior evidence of an underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care; e Platelet count ≥100 000\u002Fmm3, hemoglobin \\>9 g\u002Fdl, absolute neutrophil count \\>1,500\u002Fmm3; f Alkaline phosphatase limit ≤2∙5 × ULN (≤5 × ULN for patients with liver involvement of their cancer).\n\nExclusion Criteria:\n\n1. Previous treatment for metastatic or locally advanced disease.\n2. Previous adjuvant therapy within 1 year from the diagnosis of metastatic disease.\n3. Prior treatment with immunotherapy.\n4. Previous or concurrent cancer that is distinct in primary site or histology from urothelial cancer within 3 years before enrollment EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta \\[non-invasive tumor\\], Tis \\[carcinoma in situ\\], and T1 \\[tumor invades lamina propria\\]), pT2 prostate cancer with PSA\\\u003C0.01.\n5. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication\n6. Pregnancy or breast-feeding. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment.\n7. Any cardiological condition among:\n\n   1. Congestive heart failure of New York Heart Association class 3 or worse.\n   2. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study drug.\n   3. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted).\n   4. Uncontrolled hypertension (systolic blood pressure \\>150 mmHg or diastolic pressure \\>90 mmHg despite optimal medical management).\n   5. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), pulmonary embolism within the 4 months before start of study medication.\n8. Ongoing infection higher than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 grade 2.\n9. Known history of human immunodeficiency (HIV) virus infection or known history of chronic hepatitis B or C.\n10. Any autoimmune disease that contraindicates the use of maintenance immunotherapy in case of stable or responsive disease to chemotherapy.\n11. Seizure disorder requiring medication.\n12. Symptomatic metastatic brain or meningeal tumors unless the patient is \\>2 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also, the patient must not be undergoing acute steroid therapy or tapering (chronic steroid therapy is acceptable provided that the dose is stable for 1 month before and after screening radiographic studies).\n13. History of organ allograft.\n14. Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event of CTCAE grade 3 or higher within 4 weeks of start of study medication.\n15. Non-healing wound, ulcer, or bone fracture.\n16. Renal failure requiring hemodialysis or peritoneal dialysis.\n17. Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his or her compliance in the study.\n18. Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n19. Participation to another clinical trial at the time of the enrollment.",{"count":135,"type":20},135,[137],"PHASE4","This study aims to prospectively observe whether certain alterations in some genes related to the DNA repair mechanism are related to better response to platinum-based chemotherapy used to treat metastatic bladder or urothelial cancers.",[140,27],"Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable",[142,143,144],"DNA damage response genes","cisplatin","carboplatin","2025-02-06",{"date":147,"type":37},"2025-02-11",{"date":149,"type":37},"2025-01-07",{"date":151,"type":20},"2027-01-07",{"name":153,"class":71},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":72},"100472949","a-comprehensive-prospective-assessment-of-the-physical-and-biological-effects-of-upper-tract-urothelial-cancer-utuc-100472949","NCT05438537","A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)","Inclusion Criteria:\n\n* Male patients \\> 18 years old\n* Patients who has presence of UTUC and pending for surgery\n* Patients who has history of UTUC with any intervention performed\n\nExclusion Criteria:\n\n\\- Patients fail to provide informed consent",{"count":161,"type":20},300,"There are many controversies and limitations in the management of Upper Tract Urothelial cancer. A prospective registry is set up for patients in our hospital, aim to have a comprehensive prospective assessment of the physical and biological effects of Upper Tract Urothelial cancer in our patients",[27],"2024-01-21",{"date":166,"type":37},"2024-01-23",{"date":168,"type":37},"2021-11-01",{"date":170,"type":20},"2030-12-30",{"name":172,"class":71},"Chinese University of Hong Kong"]